His primary scientific interests are in Internal medicine, Endocrinology, Neuropeptide Y receptor, Alcohol dependence and Central nervous system. His work deals with themes such as Habituation and Peptide, which intersect with Internal medicine. His Endocrinology study integrates concerns from other disciplines, such as Ethanol and Agonist.
His Neuropeptide Y receptor study incorporates themes from Endogeny, Corticosterone and Anxiolytic. His Alcohol dependence research is multidisciplinary, incorporating elements of Acamprosate, Naltrexone and Psychiatry, Alcohol abuse. His biological study spans a wide range of topics, including Cerebral cortex, Dopamine and Cortex.
Markus Heilig mostly deals with Internal medicine, Endocrinology, Pharmacology, Alcohol dependence and Receptor. His Internal medicine course of study focuses on Alcohol and Anesthesia. The various areas that Markus Heilig examines in his Endocrinology study include Neuropeptide, Neuropeptide Y receptor and Antagonist.
Within one scientific family, Markus Heilig focuses on topics pertaining to Nucleus accumbens under Pharmacology, and may sometimes address concerns connected to Ventral tegmental area. His studies deal with areas such as Genetics, Psychiatry, Alcohol abuse, Anxiety and Clinical psychology as well as Alcohol dependence. His study in Addiction and Substance abuse are all subfields of Psychiatry.
His primary areas of investigation include Internal medicine, Endocrinology, Alcohol, Alcohol use disorder and Pharmacology. Markus Heilig has researched Internal medicine in several fields, including Single-nucleotide polymorphism, Genetic variation and Depression. Markus Heilig does research in Endocrinology, focusing on Amygdala specifically.
His Alcohol research incorporates themes from Psychiatry, Drug, Ghrelin and Opioid. His research integrates issues of Nucleus accumbens and Inverse agonist in his study of Pharmacology. His work carried out in the field of Receptor brings together such families of science as Hormone and Animal studies.
His scientific interests lie mostly in Pharmacology, Alcohol, Ghrelin, Prefrontal cortex and Internal medicine. His Pharmacology research includes elements of Cannabinoid, Fear conditioning, Endocannabinoid system and Anxiogenic. His study in Alcohol is interdisciplinary in nature, drawing from both Psychosocial, Global health, MEDLINE and Mass screening.
His research investigates the connection between Ghrelin and topics such as Alcohol use disorder that intersect with issues in Substance abuse, Clinical psychology, Neuroimaging, Neural correlates of consciousness and Functional magnetic resonance imaging. The Prefrontal cortex study combines topics in areas such as Somatosensory system, Superior temporal gyrus, Sensory system and Supramarginal gyrus. Internal medicine connects with themes related to Endocrinology in his study.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Modulation of anxiety and neuropeptide Y-Y1 receptors by antisense oligodeoxynucleotides
Claes Wahlestedt;Emilio Merlo Pich;George F. Koob;Frances Yee.
Science (1993)
The NPY system in stress, anxiety and depression.
Markus Heilig.
Neuropeptides (2004)
A key role for corticotropin-releasing factor in alcohol dependence
Markus Heilig;George F. Koob.
Trends in Neurosciences (2007)
1-year retention and social function after buprenorphine-assisted relapse prevention treatment for heroin dependence in Sweden: a randomised, placebo-controlled trial.
Johan Kakko;Kerstin Dybrandt Svanborg;Mary Jeanne Kreek;Markus Heilig.
The Lancet (2003)
Neuropeptide systems as novel therapeutic targets for depression and anxiety disorders
Andrew Holmes;Markus Heilig;Nadia M.J. Rupniak;Thomas Steckler.
Trends in Pharmacological Sciences (2003)
Anxiolytic-like action of neuropeptide Y: mediation by Y1 receptors in amygdala, and dissociation from food intake effects.
Markus Heilig;Sarah McLeod;Michelle Brot;Steven C. Heinrichs.
Neuropsychopharmacology (1993)
Centrally administered neuropeptide Y (NPY) produces anxiolytic-like effects in animal anxiety models.
Markus Heilig;Bo Söderpalm;Jörgen A. Engel;Erik Widerlöv.
Psychopharmacology (1989)
Pharmacological treatment of alcohol dependence: Target symptoms and target mechanisms
Markus Heilig;Mark Egli.
Pharmacology & Therapeutics (2006)
Corticotropin-releasing factor and neuropeptide Y: role in emotional integration.
Markus Heilig;George F. Koob;Rolf Ekman;Karen T. Britton.
Trends in Neurosciences (1994)
Acute withdrawal, protracted abstinence and negative affect in alcoholism: Are they linked?
Markus Heilig;Mark Egli;John C. Crabbe;Howard C. Becker.
Addiction Biology (2010)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:
National Institutes of Health
Central Institute of Mental Health
University of Miami
National Institutes of Health
National Institutes of Health
University of Gothenburg
National Institute on Drug Abuse
Heidelberg University
National Institute on Drug Abuse
National Institutes of Health
University of California, Berkeley
City University of Hong Kong
San Diego State University
Imperial College London
National University of Singapore
University of Malaga
University of Tennessee at Knoxville
German Cancer Research Center
University of Oklahoma Health Sciences Center
Johns Hopkins University
Xidian University
Charité - University Medicine Berlin
University of Bordeaux
Mind Research Network
Instituto de Salud Carlos III
University of Mississippi